Introduction {#Sec1}
============

The most important mode of hepatitis C virus (HCV) transmission is through exposure to infected blood \[[@CR1], [@CR2]\]. Therefore injecting drug users (DU) are at high risk for HCV infection. Their main route of transmission is the sharing of needles or other injecting equipment \[[@CR3]\]. In this population, the reported prevalences of HCV range from 40% to 85% in Europe and North America \[[@CR1], [@CR4]--[@CR11]\].

Under the threat of AIDS, DU reduced their injecting risk behavior and consequently their incidence of HIV infection in the mid-1980s \[[@CR12], [@CR13]\]. However, their HCV incidence appears to be less affected by this decreased risk behavior, perhaps because HCV is more transmissible than HIV. This hypothesis is confirmed by several studies that show a high and stable prevalence of HCV antibodies in this population \[[@CR14]--[@CR17]\]. In recent years, we reported a high but declining HCV prevalence among young DU in Amsterdam \[[@CR18]\], whereas others still report high and stable HCV incidence among young DU who have recently started injecting \[[@CR15], [@CR17], [@CR19], [@CR20]\].

The open and ongoing Amsterdam Cohort Studies (ACS) among DU started in 1985, and stored serum was retrospectively tested for HCV antibodies. Therefore, the ACS has the unique potential to present HCV incidence data for DU over two decades. The objectives of our study were to measure the HCV incidence over this long period, to evaluate risk factors associated with HCV seroconversion, and to compare the HCV incidence to the HIV incidence in this cohort over the same period.

Materials and methods {#Sec2}
=====================

The ACS is an open, prospective cohort study initiated to investigate the prevalence, incidence, and risk factors of infections with HIV-1 and other blood-borne and/or sexually transmitted diseases, as well as the effects of intervention \[[@CR21]\]. The DU cohort was initiated in 1985; recruitment is ongoing and in recent years has been directed in particular to young DU.

Participation in the ACS is voluntary, and informed consent is obtained for every participant at intake. ACS participants visit the Health Service of Amsterdam every 4--6 months. At every visit, they complete a standardized questionnaire about their health, risk behavior, and socio-demographic situation. Questions about current behavior refer to the period between the present and the preceding ACS visit. Questions at baseline refer to the period since 1980 or since the start of regular use of hard drugs. Blood is drawn for laboratory testing and storage.

Laboratory methods {#Sec3}
------------------

To study HIV prevalence and incidence, all ACS participants since 1985 (n = 1640) were prospectively tested for HIV antibodies by enzyme linked immunosorbent assays (ELISA), with confirmation by Western blot (since 1995: HIV Blot version 2.2, Genelab diagnostics).

To study the HCV prevalence and incidence, all participants with at least two visits between December 1985 and November 2005 (n = 1276) were retrospectively tested for HCV antibodies, using the first sample available in each case. Third generation ELISA tests were used to detect HCV antibodies (AxSym HCV version 3.0; Abbott, Wiesbaden, Germany). Individuals who were HCV-negative at ACS entry were tested for HCV antibodies at their most recent ACS visit. On finding HCV seroconversion, samples taken in between these two visits were tested to identify the moment of seroconversion.

Statistical analyses {#Sec4}
--------------------

The date of HCV or HIV seroconversion was estimated as the midpoint between the last seronegative and the first seropositive ACS visit. The median duration of the HCV seroconversion interval between visits was 4.0 months, interquartile range (IQR) 3.7, 5.1 months. Using the Kaplan-Meier method, we examined the time elapsed from the start of injecting drugs to HCV seroconversion. Only HCV-negative DU were included and they were considered to be at risk from their start of injecting. Those who had started injecting before ACS enrolment entered the risk set at their date of ACS entry (i.e., left truncation). Those who did not seroconvert or who were lost to follow-up were censored at their last ACS visit or ultimately 1 November 2005. We stratified the dates of starting injection into two decennia to investigate differences in HCV-free survival according to decade of starting injection.

Incidence rate curves were calculated by person-time methods. Poisson regression was used to test for the trend in HCV incidence over time and to determine risk factors for HCV seroconversion. All variables subject to change were treated as time-dependent variables. Due to the relatively long time-period between the point of infection and the appearance of HCV antibodies \[[@CR22]\], the most probable moment of infection was assumed to have occurred around the last seronegative visit. Therefore, we assigned the risk behavior reported at that visit to the HCV seroconversion period. However, for nine participants who reported starting injection at the first HCV antibody-positive visit, we set back the report of injecting risk factors from this visit to the last HCV antibody-negative visit. Multivariate models were built using forward-stepwise techniques, and variables with a univariate *p*-value \< 0.20 were considered as potential independent determinants. A *p*-value \< 0.05 was considered statistically significant \[[@CR23], [@CR24]\]. Interactions in the final model were checked.

Variables related to general characteristics, drug use, and sexual risk behavior were examined as potential determinants of HCV seroconversion. General characteristics included sex, body mass index, calendar year of study visit, nationality, ethnicity, age, homelessness, hospitalization, and HIV status. The drug use variables included current injecting and the calendar period of starting injection. For current injectors, we also examined the frequency of injecting, the main type of drug injected, whether they injected mainly at home or borrowed needles, and needles obtained through a needle exchange program (NEP). Because there was a very strong association between current injecting and current borrowing of needles, we combined these two variables as follows: no current injecting; current injecting but no current borrowing of needles; current injecting and current borrowing of needles. Sexual behavior included having a steady sexual partner, injecting drug use of the steady partner, having unprotected sex (with an injecting partner), and current prostitution (women only).

To compare the HCV and HIV incidence, we assumed that the observed data (i.e., the number of new infections per year) follows a Poisson distribution. We adopted a Bayesian approach. The logarithm of the incidence over calendar time was modeled using penalized splines. In this way, the incidence of both HCV and HIV was allowed to vary smoothly and nonlinearly over time \[[@CR25]--[@CR27]\]. If the trends have the same pattern, then the difference between the incidences on a logarithmic scale is a constant.

Results {#Sec5}
=======

General characteristics and HCV prevalence {#Sec6}
------------------------------------------

In total, 1640 DU have been enrolled in the ACS since December 1985. Of these, 1259 DU met the follow-up criteria of at least two visits before November 2005 and also had enough stored serum to allow HCV testing. Of these participants, 803/1259 (63.8%) were male and 937/1259 (74.5%) had a Dutch nationality. The median age at ACS entry was 30.5 years (IQR 26.5, 35.8) (Table [1](#Tab1){ref-type="table"}). Table 1General characteristics of drug users in the Amsterdam Cohort StudyTotalEver-injecting DUNever-injecting DUTotal number of participants1259952307Median age^a^ (IQR)30.5 (26.5, 35.8)29.84 (26.0, 36.0)30.6 (26.8, 35.7)% Male sex63.861.371.3% Dutch nationality74.786.071.0Median duration of follow-up (IQR)6.95 (3.56, 12.1)7.33 (3.84, 12.6)5.41(2.60,10.4)5.41 (2.60, 10.4)Median age at start of injecting drugs (IQR)---21.7(17.8,26.0)---Main drugs injected (%)^a^------Cocktail, heroin/cocaine40.0Heroin12.2Cocaine8.9---Main other drugs used (%)^a^------Cocktail, heroin/cocaine4.441.0Heroin31.543.0Cocaine26.74.2Frequency of injecting (%)------No current injecting28.5Daily34.0Weekly30.7Monthly4.4Number of recently borrowed needles(%)^a^------044.91--107.6\> 100.9Unknown46.4% HCV-antibody positive^a^63.882.26.5HCV seroconversions during follow-up59581% HIV-positive^a^20.425.83.6HIV seroconversions during follow-up95905Ever-injecting DU: DU who had injected before ACS entry (n = 905) or started injecting during follow up (n = 47).Current/recently: in previous 6 months.^a^ At entry.

Of the 1259, 952 participants were ever-injectors: DU who had ever injected drugs before entry (n = 905) or who had started injecting drugs during follow up (n = 47). The median age at start of injection was 21.7 years (IQR 17.8, 26.0).

The median ACS follow-up time for ever-injectors was 7.3 years (IQR 3.8,12.6), whereas it was 5.4 years (IQR 2.6, 10.4) for never-injectors. In ever-injectors, the main drugs recorded at ACS entry were a cocktail of heroin and cocaine (40.0%), and most participants had injected daily or more frequently in the preceding 6 months (34.0%).

Of the 1259 DU, 803 (63.8%) had HCV antibodies at entry; of these, 30.6% (246/803) were HIV-co-infected. The prevalence at entry of HCV antibodies in ever-injectors varied from 92.9% in 1986 to 69.2% in 2001. The prevalence among never-injectors was 6.5% over the total study period and varied from 0% to 22.2% per calendar year.

When evaluating HCV prevalence at entry by the time elapsed since start of injection, such prevalence was 59/99 (59.6%) for participants who had injected for less than 2 years before entry vs. 137/164 (82.5%) for participants who had injected for 3--5 years before entry. Among participants with \>10 years of injecting drug use before ACS entry, the HCV prevalence was 327/346 (94.5%).

HCV incidence {#Sec7}
-------------

Of the 456 DU seronegative for HCV at ACS entry, 59 seroconverted during follow-up, of whom 58 injected and 1 did not. Among ever-injectors, the incidence declined from 27.5/100 PY in the late 1980s to approximately 2/100 PY in recent years (Figure [1a](#Fig1){ref-type="fig"}). There was a significant downward trend in HCV incidence over calendar time (IRR 0.86 per calendar year; 95% CI 0.82, 0.90, *p* \< 0.001) (Figure [1a](#Fig1){ref-type="fig"}). Figure 1(a, b) Observed HIV and HCV incidence curves among ever injecting DU in the ACS (1985--2005); (c) observed and fitted HCV (left y-axis) and HIV (right y-axis) incidence curves among ever injecting DU in the ACS (1985--2005).

In line with the decline of the HCV incidence, the time since starting injection until HCV seroconversion has lengthened in more recent calendar periods. In 1980--1989, the median interval was 2.27 years (IQR 1.2, 5.6 years), whereas in 1990--1999, the median was 9.10 years (IQR 2.1, ∞ years) (Figure [2](#Fig2){ref-type="fig"}). Figure 2Kaplan-Meier estimates of the cumulative proportion of DU who remain without HCV infection since starting injection, grouped per decennium: the 1980s (lower line) and 1990s (upper line). Curves were truncated when fewer than 10 persons remained at risk for HCV (thin line). Persons who started injecting before 1980 or after 2000 are not depicted in this figure, because at any moment in those periods, less than 10 persons were at risk for HCV.

When restricting our analysis to DU who reported injecting since the preceding visit, a higher incidence but similar pattern was observed. In 1985--1990, the incidence rate in this group was extremely high, between 50--80/100 PY, but it dropped to 5--10/100 PY in 1990--1999.

Comparison of HCV and HIV incidence {#Sec8}
-----------------------------------

Of 1276 DU, those HIV-negative at entry numbered 1013, of whom 95 (including 90 ever-injectors) seroconverted for HIV during follow-up. The HIV incidence rate among ever-injectors dropped from 8.52/100 PY in 1986 to approximately 0 since 2000, with a slight increase in 2005 (Figure [1b](#Fig1){ref-type="fig"}).

When the observed HCV and HIV incidence curves and their fitted smooth curves are plotted in one graph with two scales, the curves look similar in shape. When we plotted the differences between the logs of the fitted model, we found no convincing evidence for a difference in pattern. The mean value of the differences on a log-scale over the twenty years is 1.48; hence the scale factor is estimated to be 4.4 (data not shown). The observed and fitted incidence patterns for both HCV and HIV with 95% confidence intervals are shown in Figure [1c](#Fig1){ref-type="fig"}.

Risk factors for HCV seroconversion {#Sec9}
-----------------------------------

Time since start injecting can be seen as a proxy for the duration of exposure time, and preliminary analysis showed a very strong association between time since start of injecting and the timepoint of HCV seroconversion (IRR 0.80 per year), 95% CI 0.74, 0.86) (Table [2](#Tab2){ref-type="table"}). Therefore, in bivariate analysis, to adjust for variation in time from start of injecting (and thus time of exposure), all other variables were adjusted for time from start of injecting as a time-updated variable. Table 2Univariate, bivariate, and multivariate IRR of potential risk factors for HCV infectionUnivariate analysisBivariate analysis^\*^Multivariate analysisHCVscPYIncidence rate (per 100 PY)IRR95% Cl*p* ValueIRR95% Cl*p* ValueIRR95% Cl*p* ValueMethadone dosage0 mg344088.332.23(0.68, 7.26)0.181.07(0.33, 3.51)0.921--59 mg methadone203585.591.49(0.44, 5.02)0.95(0.28, 3.21)\> 60 mg3803.7511HIV statusHIV-negative518316.1410.00610.25HIV primary infection51435.75.68(2.27, 14.2)2.18(0.85, 5.57)HIV chronically infected21020.03.12(0.76,12.8)1.95(0.47, 8.07)Decennium of starting injection1970--197911460.6810.00210.13^\*\*^1980--1989374438.3512.2(1.67, 88.9)1.56(0.19, 12.6)1990--1999192397.9511.6(1.55, 86.6)1.01(0.12, 8.37)2000--present1234.356.26(0.39, 100.0)0.32(0.02, 5.74)Use of NEPsNo current injecting106231.611\< 0.0011\< 0.001Current injecting, no NEP189219.612.3(5.66, 26.6)7.61(3.43, 16.8)Current injecting, irregular NEP113630.619.1(8.09, 44.9)8.40(3.39, 20.8)Current injecting, always NEP199919.211.9(5.53, 25.6)7.87(3.58, 17.3)Age (per 10 years)588566.780.45(0.31, 0.65)\< 0.0010.87(0.59, 1.26)0.45Type of drugs mainly injectedNo current injecting106231.611\< 0.0011\< 0.001Heroin94619.812.2(4.97, 30.1)7.18(2.86, 18.0)Cocaine104124.415.2(6.31, 36.4)8.69(3.53,21.4)Cocktail, heroin/cocaine2111518.311.4(5.37, 24.2)6.51(2.99, 14.2)Amphetamines21711.87.46(1.64, 34.1)3.81(0.82, 17.6)Methadone3933.321.3(5.87, 77.5)35.5(9.7, 129.5)Other/unknown3475.044.6(12.3, 162.2)25.6(7.00, 93.5)Frequency of injectingNo current injecting106231.601\< 0.0011\< 0.001More times per day174934.721.7(9.92, 47.3)10.4(4.54, 23.9)Once daily1425.515.9(2.03, 124.3)12.2(1.55, 95.9)More times per week196628.818.0(8.36, 38.6)10.5(4.75, 23.3)Once weekly1128.235.13(0.66, 40.1)5.27(0.67,41.2)More times per month3378.135.07(1.40, 18.4)2.71(0.72, 10.1)Once monthly21315.29.46(2.07, 43.2)8.18(1.79, 37.4)Less than once monthly4488.365.21(1.63, 16.6)4.19(1.31, 13.4)Frequency of non-injecting drug useMore times per day212498.430.73(0.25, 2.14)0.350.60(0.20, 1.74)0.39Once daily2385.260.45(0.08, 2.48)0.45(0.08, 2.47)More tomes per week162356.810.59(0.20, 1.77)0.60(0.20, 1.80)Once weekly2682.940.25(0.05, 1.39)0.20(0.04, 1.09)More times per month2474.260.37(0.07, 2.03)0.47(0.09, 2.58)Less than once monthly0170.0011Type of drugs mainly used (non-injecting)Heroin203116.4310.9810.81Cocaine243327.231.12(0.62, 2.03)1.33(0.73, 2.41)Cocktail heroin/cocaine2326.250.96(0.22,4.11)1.07(0.25, 4.58)Amphetamines1137.691.16(0.16, 8.66)1.48(0.20, 11.0)Having a steady partnerNo364967.261.19(0.70, 2.02)0.521.55(0.91, 2.64)0.10Yes223606.1111Injecting drug use of the steady partnerNo122554.7110.1010.99Yes101059.522.04(0.88, 4.71)0.99(0.42, 2.33)HomelessnessNo528006.500.61(0.26, 1.43)0.290.67(0.29, 1.57)0.39Yes65710.511Hospitalized in past 6 monthsNo568176.851.34(0.33, 5.50)0.671.36(0.33, 5.59)0.65Yes2395.1311Current prostitution (females only)No242439.8810.1910.82Yes2474.260.43(0.10, 1.81)1.19(0.28, 5.07)Current injecting and borrowing needlesNo current injecting106231.611\< 0.0011\< 0.0011\< 0.001Current injecting, no current borrowing of needles2515915.79.80(4.71, 20.4)6.26(2.94, 13.3)8.70(4.03, 18.8)Current injecting and current borrowing of needles122352.232.7(14.1, 75.7)21.4(9.17, 50.1)29.9(12.6, 70.9)Time since start of injecting588566.80.80(0.74, 0.86)\< 0.0010.89(0.83, 0.96)\< 0.001Year of visit588566.80.86(0.82, 0.90)\< 0.0010.94(0.89, 0.99)0.0090.87(0.82, 0.93)\< 0.001SexMale325665.6510.08510.36Female262908.971.59(0.95, 2.66)1.28(0.76, 2.16)^\*^ Adjusted for time since start of injection.^\*\*^ Analyses were not adjusted for time since start of injection and decennium of start, because the decennium can be derived from the time since start of injection and calendar year of visit.

After correction for time since starting injection, the following risk factors were found to be significantly associated with an increased risk of HCV seroconversion: the combined variable of current injecting and current borrowing of needles, earlier calendar year of visit, use of NEP, type of drugs injected, frequency of injecting drug use, and earlier decennium of starting injection (Table [2](#Tab2){ref-type="table"}). Interestingly, in univariate analysis persons were more at risk for HCV if they had seroconverted for HIV (IRR 5.68; 95% CI: 2.27, 14.2) or were chronically infected with HIV (IRR 3.12; 95% CI: 0.76, 12.8) than if they were HIV-negative. The type of drugs injected, and frequency of injection were associated with an increased risk of HCV infection, their effect is attributable to current injecting drug use itself. In fact, when evaluating these variables among only DU injecting drugs within the past 6 months we found no association between NEP use, the type of drug injected, or injection frequency and HCV infection.

In multivariate analysis, we found that current injecting combined with current borrowing of needles was a major risk for HCV seroconversion; the IRR was 29.9 (95% CI: 12.6, 70.9) for current injecting and borrowing compared to no injecting in the preceding period. The longer the time between start of injecting and study visit, the smaller the risk of HCV infection: IRR 0.89; 95%CI: 0.83, 0.96) (Table [2](#Tab2){ref-type="table"}). Calendar year remained significantly associated with a decreased risk of HCV infection when it was evaluated continuously in the model (IRR 0.87; 95% CI: 0.82, 0.93).

Discussion {#Sec10}
==========

This study describes the prevalence and incidence of HCV in a large group of DU in Amsterdam, the Netherlands, over two decades. Findings show that the HCV incidence dropped considerably in that period. Interestingly, when we compared the HCV incidence rate to the HIV incidence rate in the same group of DU that have ever injected, the decrease was similar for the two infections. In line with the decline of the HCV incidence, the time from the start of injecting drugs until HCV seroconversion is longer at present than in the past.

To our knowledge, this is the first study to document among DU, over such a long period, a decline in HCV incidence that is not only strong but also comparable to the decline in HIV incidence. Our finding of a decline in HCV incidence contrasts with other studies that show a stable HCV incidence \[[@CR19], [@CR28]\]. One explanation may be that those studies analyzed the HCV incidence over a shorter time interval, which might have been insufficient to show a significant decline. In Baltimore, USA, a significant decline of the HCV incidence was found in injecting DU followed between 1988 and 1996, but in contrast to our study with ongoing recruitment of participants, this decline was observed in a closed cohort study and a saturation effect probably has contributed to this decline \[[@CR29]\].

In addition, the risk behavior of the total group of DU included in the ACS has substantially declined over time in Amsterdam \[[@CR30]\]. This finding suggests that a decline in risk behavior at the population level has contributed to the simultaneous decline of HCV and HIV incidence. The decreasing HCV incidence in Amsterdam DU, as opposed to high incidences in DU elsewhere, may likewise be partly explained by a larger reduction in injecting risk behavior in Amsterdam, compared to reductions elsewhere. The impact of methadone provision and NEP on this decline of risk behavior is very important and should be a focus of future studies. Methadone and NEP were readily available throughout the study period, and the median prescribed daily methadone dose increased during this period. Murray et al. \[[@CR31]\] demonstrated by mathematical modeling that the level of risk behavior determines whether HCV incidence decreases. They calculated that if injecting risk behavior is sufficiently decreased (through intense NEP and/or harm reduction strategies), then HCV incidence will accordingly decline.

Mathematical models have additionally shown the natural course of an epidemic might bring a decline in the incidence of infection \[[@CR32]\]. When a new infectious agent enters a population, the number of infected individuals and the incidence soon increase. Thereafter, as the number of susceptibles decreases, the chance for an infected individual to come into contact with an uninfected individual decreases as well. When the density of uninfected persons reaches a threshold below which the number of susceptibles cannot sustain an ongoing epidemic, incidence peaks and then starts to decline. In this light, the decrease in HIV incidence observed shortly after the introduction of HIV in Amsterdam in the early 1980s was due to the depletion of susceptibles, along with a reduction in risk behavior. However, such depletion is less likely to be the case for HCV, which has existed among DU since the 1960s and possibly even before \[[@CR33], [@CR34]\]. This implies that the decrease in injecting risk behavior might have an even greater impact on HCV than on HIV.

The contrast in study findings may be explained in part by the HCV test used. We used third-generation ELISA tests to measure HCV antibodies, whereas studies from the late 1980s/early 1990s used first- or second-generation ELISA tests, which were more inclined to give false positive test results \[[@CR35]\].

The HCV prevalence among DU at ACS entry varies between 70% and 90%, with lower prevalence rates in recent years. This is consistent with what was described among DU in Amsterdam in the early 1990s \[[@CR28]\] and among recently starting injectors in Amsterdam and elsewhere \[[@CR18], [@CR36]\]. The HCV prevalence in never-injecting DU is much lower than in ever-injectors but still much higher than in low-risk populations (e.g., blood donors) or the general populations in Western countries \[[@CR1], [@CR37]\], household transmission, rare sexual transmission, and reliability/unreliability of answers given in interviews may contribute to this finding among never-injecting DU.

Among DU in Amsterdam who have injected in the past 6 months, incidence rates were extremely high in the 1980s (50--80/100 PY). Similarly high incidence rates have been described by Smyth et al. among young, DU who have recently started injecting in Ireland, in the 1990s \[[@CR10]\].

A possible limitation of our study is its lack of confirmatory testing for positive results of HCV antibody testing. However, such results in a high-risk population are likely to be true positives \[[@CR35]\], and 232/803 (28.9%) of the positive participants were tested at two study visits or more, all with consistent HCV-positive test results. Therefore we believe the lack of confirmatory testing did not influence our results. Furthermore, although the ACS is an open, prospective cohort study, the influx of new participants in recent years has been lower than in earlier years. Lower risk DU could be overrepresented due to the decease of high-risk DU. However, the most recent HCV seroconversions took place in young DU who entered the cohort after 1994.

Our risk factor analysis showed that HCV seroconversion is associated not only with current injecting and borrowing needles, as expected, but also with calendar year and time since start of injecting. The majority (70%) of HCV infections could have been prevented by eliminating the borrowing of needles. This might partly reflect the effect of the use of NEP, which were always available during the study period, but individual factors also might play a role in the decision to use NEP.

In conclusion, HCV incidence in our cohort showed a sharp decline in the past two decades, similar to the decline in HIV incidence, most likely due to a decrease in injecting risk behavior. We found that those who started injecting in a recent calendar period are at lower risk of HCV infection, presumably due to prevention activities. Thus it is important to continue and enhance such activities among DU and others at risk of starting injection, especially because the HCV risk is highest just after the start of injecting, when probably injectors are inexperienced.

Although we did not find an independent effect from either participation in a methadone program or from the use of NEP, these prevention measures in combination are likely to have contributed to the decline in risk behavior related to drug use at the population level. Therefore, it is important to evaluate the possibilities for harm reduction worldwide. During the late 1980s many acute HCV infections occured, so there might have been more DU with high HCV RNA levels associated with acute HCV infection. Therefore, in that period there may have been more and/or easier transmission of HCV. Higher HCV RNA levels have also been associated with HIV co-infection \[[@CR38]\]. However, we believe that because the HCV prevalence remained relatively high and the pattern of the HIV and HCV incidence was comparable during the study period, on population level the HCV RNA level varied only little over time, also because treatment prescription for HCV was very limited in our cohort.

Finally, it is important to decrease the prevalence of chronic HCV carriers and thus reduce the possibility for HCV transmission. DU should therefore be systematically screened for HCV infection, and those chronically infected should be treated \[[@CR39]\].
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